These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21648229)

  • 1. Methods for improving the reporting of adverse effects.
    Prescrire Int; 2011 Mar; 20(114):71. PubMed ID: 21648229
    [No Abstract]   [Full Text] [Related]  

  • 2. Advantages of adverse-effect reporting by patients.
    Prescrire Int; 2011 Mar; 20(114):70. PubMed ID: 21648228
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements.
    Kingston R
    Thromb Res; 2005; 117(1-2):137-44; discussion 145-51. PubMed ID: 16139875
    [No Abstract]   [Full Text] [Related]  

  • 5. Reporting adverse effects: a practice to be encouraged.
    Prescrire Int; 2013 Mar; 22(136):83. PubMed ID: 23593701
    [No Abstract]   [Full Text] [Related]  

  • 6. Compliance in European pharmacovigilance: a regulatory view.
    Arlett PR; Harrison P
    Pharmacoepidemiol Drug Saf; 2001; 10(4):301-2. PubMed ID: 11760490
    [No Abstract]   [Full Text] [Related]  

  • 7. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical reflection on the collection and evaluation of adverse drug reaction data.
    Venulet J
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691
    [No Abstract]   [Full Text] [Related]  

  • 9. [French system of drug surveillance].
    Imbs JL; Castot A; Begaud B; Larousse C; Blayac JP; Alexandre JM
    Bull Acad Natl Med; 1998; 182(7):1383-91; discussion 1392-3. PubMed ID: 9916332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S
    Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine adverse event reporting: the importance of follow-up.
    Varricchio F
    Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
    [No Abstract]   [Full Text] [Related]  

  • 13. Factors that influence spontaneous reporting of adverse drug reactions: a model centralized in the medical professional.
    Herdeiro MT; Polonia J; Gestal-Otero JJ; Figueiras A
    J Eval Clin Pract; 2004 Nov; 10(4):483-9. PubMed ID: 15482410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of spontaneous reporting of adverse drug reactions (ARDs) in Zimbabwe.
    Ball D
    Cent Afr J Med; 2000 Jan; 46(1):23-4. PubMed ID: 14674204
    [No Abstract]   [Full Text] [Related]  

  • 15. Suggestions for improving the monitoring of adverse events following immunization in New Zealand.
    Miller M; Turner N
    N Z Med J; 2002 Sep; 115(1162):U186. PubMed ID: 12386665
    [No Abstract]   [Full Text] [Related]  

  • 16. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 17. MEDWatch: the new FDA medical products reporting program.
    Kessler DA
    Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
    [No Abstract]   [Full Text] [Related]  

  • 18. Health authorities and drug utilization studies.
    Garcia Alonso F; Scott AI; Stika L; Westerholm B
    WHO Reg Publ Eur Ser; 1993; 45():147-67. PubMed ID: 8442843
    [No Abstract]   [Full Text] [Related]  

  • 19. [Joint program of pharmacovigilance in Quebec: comparison with France, Aquitaine and the Basque region].
    Biron P; Balency D
    Therapie; 1996; 51(5):578-81. PubMed ID: 9138400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug surveillance: concepts, objectives, and methods].
    Susano RC; Laborinho Fialho L; de Quirós JF
    Acta Med Port; 1992 Dec; 5(11):595-602. PubMed ID: 1293954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.